http://dx.doi.org/10.1016/j.seizure.2015.08.002 1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights re A 44-year-old woman with epilepsy since youth and no previous cardiovascular event, was admitted to the epilepsy unit for a thorough study with video-EEG. She usually had several complex partial seizures every month, although occasionally presented generalized e...

+*McAllister, D (A-American Orthopaedic Society for Sports Medicine (AOSSM) First Time Investigator Award); *Markolf, K; *Oakes, D; *McWilliams, J; *Young, C +*UCLA Medical Center Department of Orthopaedic Surgery, Los Angeles, CA 90095-6902. Department of Orthopaedic Surgery UCLA Center for Health Sciences, Box 956902, Los Angeles, CA 90095-6902, 310-206-5250, Fax: 310-825-1311, DMcAllister@Me...

ID: 1311 Hornung, Johanna; Hornung, Christoph Fraunhofer Institute Computer Graphics Dept. e-Learning & Knowledge Management Rundeturmstr. 6 D-64283 Darmstadt, Germany [email protected] [email protected] Oliveira, Alexandre aCentro de Computação Gráfica Rua Rodrigues Gusmão, 21 Coimbra, Portugal {aoliveira, marcos}@ccg.pt Fernandes Marcos, Adérito a,b bMinho University Dept....

INTRODUCTION........................................................................1299 I. THE QUEST FOR “CURES” ......................................................1303 II. FAILED EFFORTS TO MAKE “HOMOSEXUALS” SICK......1311 A. WHAT MAKES A PERSON MENTALLY ILL .............................1313 B. THE DEPATHOLOGIZATION OF HOMOSEXUALITY.................1316 C. CAUSAL THEORIES OF DISORDER........

understanding the design parameters of drug formulations Author(s) Yamashita, Fumiyoshi; Itoh, Takayuki; Yoshida, Shuya; Haidar, Mohammad K.; Hashida, Mitsuru Citation Computers & Chemical Engineering (2010), 34(8): 1306-1311 Issue Date 2010-08-09 URL http://hdl.handle.net/2433/128765 Right © 2009 Elsevier Ltd Type Journal Article Textversion author KURENAI : Kyoto University Research Informati...

5-Diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311 (NSC-645809), is an antitumor agent shown to be effective against breast cancer in phase II clinical trials. A similar compound, 5-dimethylaminopropylamino-8-hydroxytriazoloacridinone, C-1305, shows high activity against experimental tumors and is expected to have even more beneficial pharmacological properties than C-1311. Previously ...